Literature DB >> 9780274

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure.

B Young1, S Johnson, M Bahktiari, D Shugarts, R K Young, M Allen, R R Ramey, D R Kuritzkes.   

Abstract

High-density oligonucleotide arrays were used to determine the sequence of the protease (PR) and reverse transcriptase (RT) genes of human immunodeficiency virus type 1 isolates from 35 patients in whom combination therapy that included a protease inhibitor had failed. Isolates had a median of three PR mutations (range, none to six). Three isolates had no known resistance mutations in PR. Twelve isolates (34%) had two or fewer resistance mutations in PR. The most commonly observed PR mutations were L10I, V82A/T/F, and L90M. No mutations were observed at codons 30 or 48. Mutations at RT codons 215 and 184 were observed in the majority of isolates. These data suggest that therapy can fail in some patients with relatively few PR resistance mutations. Clinical failure in the absence of resistance mutations implies inadequate drug exposure due to pharmacologic factors or suboptimal patient adherence to drug therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780274     DOI: 10.1086/314437

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

Authors:  B Bühler; Y C Lin; G Morris; A J Olson; C H Wong; D D Richman; J H Elder; B E Torbett
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.

Authors:  P A Cane; A de Ruiter; P Rice; M Wiselka; R Fox; D Pillay
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.

Authors:  S La Seta Catamancio; M P De Pasquale; P Citterio; S Kurtagic; M Galli; S Rusconi
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 5.  Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

Authors:  John H Elder; Ying-Chuan Lin; Elizabeth Fink; Chris K Grant
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

6.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

Review 7.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

8.  Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients.

Authors:  M C Re; P Monari; I Bon; D Gibellini; F Vitone; M Borderi; M La Placa
Journal:  BMC Microbiol       Date:  2001-11-27       Impact factor: 3.605

Review 9.  A role for arrays in clinical virology: fact or fiction?

Authors:  Jonathan P Clewley
Journal:  J Clin Virol       Date:  2004-01       Impact factor: 3.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.